Egilius Spierings
Neurology · Wellesley Hills, MANPI 1487748703
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $620,462 of the $679,586 with a category attached, or 91.3%. 14 manufacturers reported payments, led by AbbVie at 32.6% of the total. Reporting peaked in 2019 at $190,091 and has fallen 71.2% since, to $54,797 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 846 payments — averaging $803.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$221K
- Teva Pharmaceuticals USA, Inc.$151K
- Lilly USA, LLC$129K
- Lundbeck LLC$71K
- Amgen$53K
- Pfizer$22K
- plus $32K from 8 others
Across 171 payments — averaging $12,623 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$807K
- H. Lundbeck A S$318K
- Teva Pharmaceuticals USA, Inc.$233K
- Eli Lilly$182K
- Novartis$164K
- Biohaven Pharmaceutical Holding Company Ltd.$163K
- plus $291K from 5 others
What the payments were for
- Consulting fees$22,5233%
- Speaking & faculty fees$620,46291%
- Grants$880%
- Travel & lodging$21,9463%
- Food & beverage$14,3282%
- Education$2400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 236 | $221,251 |
| Teva Pharmaceuticals USA, Inc. | 141 | $150,831 |
| Lilly USA, LLC | 187 | $129,323 |
| Lundbeck LLC | 100 | $70,783 |
| Amgen | 70 | $53,095 |
| Pfizer | 34 | $22,119 |
| Biohaven Pharmaceuticals, Inc. | 32 | $17,112 |
| Biodelivery Sciences International, Inc. | 13 | $9,017 |
| Biohaven Pharmaceutical Holding Company Ltd. | 20 | $5,436 |
| Collegium Pharmaceutical, Inc. | 4 | $224 |
| Novartis | 4 | $224 |
| Impel Pharmaceuticals Inc. | 1 | $80 |
| Sunovion Pharmaceuticals Inc. | 3 | $71 |
| Boston Scientific | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$679,586 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 63 | $80,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $221,251 | $80,15263 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Wellesley Hills
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Thomas ScammellBoston$617K
- Salvatore NapoliFoxboro$613K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
- Kenneth GorsonWellesley$414K
- Roy FreemanBoston$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.